An2 Therapeutics, Inc. has entered into a Rights Agreement that grants stockholders a right to purchase preferred stock, aiming to protect against hostile takeovers, with each right allowing the purchase of one one-thousandth of a share of Series A Preferred at $6.50 until August 15, 2025.